Publication | Closed Access

A Formulation Strategy for Gamma Secretase Inhibitor ELND006, a BCS Class II Compound: Development of a Nanosuspension Formulation with Improved Oral Bioavailability and Reduced Food Effects in Dogs

Improved Oral BioavailabilityFormulation StrategyMedicinePharmacotherapyNanosuspension FormulationDrug DevelopmentPharmacologyPharmacokineticsBiomolecular EngineeringDrug Discovery